Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study

Annals of the Rheumatic Diseases

Volumn 71, Issue 10, 2012, Pages 1692-1697

  Bakker, Marije F ^a   Cavet, Guy ^b   Jacobs, Johannes W G ^a   Bijlsma, Johannes W J ^a   Haney, Douglas J ^b   Shen, Yijing ^b   Hesterberg, Lyndal K ^b   Smith, Dustin R ^b   Centola, Michael ^c   Van Roon, Joel A G ^a   Lafeber, Floris P J G ^a   Welsing, Paco M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Crescendo Bioscience   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CYCLOSPORIN; EPIDERMAL GROWTH FACTOR; GLYCOPROTEIN GP 39; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LEPTIN; MACROPHAGE DERIVED CHEMOKINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDINOLINE; RESISTIN; SERUM AMYLOID A; STROMELYSIN; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CLASSIFICATION ALGORITHM; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; PATIENT CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; METHOTREXATE; ROC CURVE;

EID: 84866072966     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200963     Document Type: Article

References (34)

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22:1-12. (Pubitemid 38269929)
2. Atar D, Birkeland KI, Uhlig T. 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. Ann Rheum Dis 2010;69:629-30.
3. Kiely PD, Brown AK, Edwards CJ, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford) 2009;48:765-72.
4. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
5. Bakker MF, Jacobs JW, Verstappen SM, et al. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Annals of the rheumatic diseases 2007;66 Suppl 3:iii56-60. (Pubitemid 350032636)
6. Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010;69:1849-52.
7. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9. (Pubitemid 350032650)
8. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:663-75. (Pubitemid 47163601)
9. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
10. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
11. Hart LE, Tugwell P, Buchanan WW, et al. Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol 1985;12:716-7. (Pubitemid 15229665)
12. Thompson PW, Hart LE, Goldsmith CH, et al. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol 1991;18:661-5.
13. Uhlig T, Kvien TK, Pincus T. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2009;68:972-5.
14. Pincus T. The American College of Rheumatology (ACR) Core Data Set and derivative "patient only" indices to assess rheumatoid arthritis. Clin Exp Rheumatol 2005;23 (5 Suppl 39):S109-13. (Pubitemid 46661467)
15. Crowson CS. Rheumatoid arthritis and heart disease: the chicken and the egg? J Intern Med 2010;268:552-4.
16. Chambers RE, MacFarlane DG, Whicher JT, et al. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis 1983;42:665-7. (Pubitemid 14205433)
17. Urata Y, Uesato R, Tanaka D, et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis 2011 2012;71:534-40.
18. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999;38:618-26. (Pubitemid 29507329)
19. Mease PJ. The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clin Exp Rheumatol 2011;29:567-74.
20. Kotzin BL, Falta MT, Crawford F, et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000;97:291-6. (Pubitemid 30055824)
21. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004;380:651-9. (Pubitemid 38850506)
22. Ozgonenel L, Cetin E, Tutun S, et al. The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:473-7.
23. Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003;62:1094-9. (Pubitemid 37323575)
24. Eastman S, Manning B, Qureshi F, et al. Assay development for precise measurement of disease activity serum biomarkers. Annals of the rheumatic diseases 2010;69:179.
25. Cavet G, Centola M, Shen Y, et al. Development of a multi-biomarker test for rheumatoid arthritis (RA) disease activity. Annals of the rheumatic diseases 2010;69:148.
26. Verstappen SM, Bakker MF, Heurkens AH, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 2010;69:1044-8.
27. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
28. Bijlsma JWJ, Oude Heuvel CHB, Zaalberg A. Development and validation of the Dutch questionnaire capacities of daily life (VDF) for patients with rheumatoid arthritis. Rehabil Sci 1990;3:71-74. (Pubitemid 20307173)
29. Fleischmann RM, Curtis JR, Hamburger MH, et al. RA population characteristics in InFoRM, a longitudinal observational study. Ann Rheum Dis 2010;69:657.
30. Inoue E, Yamanaka H, Hara M, et al. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 2007;66:407-9. (Pubitemid 46579645)
31. Benjamini Y, Hochberg M. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B, Statistical methodology 1995;57:289-300.
32. Schipper LG, van Hulst LT, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010;49:2154-64.
33. Abdelmonem A, Clark VA, May S. Computer-Aided Multivariate Analysis, Fourth Edition. Boca Raton, Florida: Chapman and Hall/CRC 2004:1?489.
34. Shen Y, Dirven L, Cavet G, et al. Serum biomarkers predict progressive structural damage in the BeSt study. Arthritis Rheum 2010;62:1496.